Uncategorized
EyeGate acquires Jade Therapeutics
EyeGate Pharmaceuticals has acquired Jade Therapeutics, according to a press release. “The integration of Jade into EyeGate significantly strengthens our market position through the addition of a robust preclinical pipeline that complements EyeGate’s ongoing efforts to develop novel treatments for diseases of the eye,” Stephen From, president and CEO of EyeGate, said in the release.